BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 28524341)

  • 1. Randomized controlled study of a novel triple nitazoxanide (NTZ)-containing therapeutic regimen versus the traditional regimen for eradication of Helicobacter pylori infection.
    Shehata MA; Talaat R; Soliman S; Elmesseri H; Soliman S; Abd-Elsalam S
    Helicobacter; 2017 Oct; 22(5):. PubMed ID: 28524341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 2-week Nitazoxanide-based quadruple treatment as a rescue therapy for Helicobacter pylori eradication: A single center experience.
    Abd-Elsalam S; Kobtan A; El-Kalla F; Elkhalawany W; Nawasany SE; Saif SA; Yousef M; Ali LA; Soliman S; Mansour L; Habba E; Soliman H; Rizk F; Shehata MA
    Medicine (Baltimore); 2016 Jun; 95(24):e3879. PubMed ID: 27310977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of sequential and standard triple-drug regimen for Helicobacter pylori eradication: a 14-day, open-label, randomized, prospective, parallel-arm study in adult patients with nonulcer dyspepsia.
    Uygun A; Kadayifci A; Yesilova Z; Safali M; Ilgan S; Karaeren N
    Clin Ther; 2008 Mar; 30(3):528-34. PubMed ID: 18405790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study of Helicobacter pylori eradication rates of twice-versus four-times-daily amoxicillin administered with proton pump inhibitor and clarithromycin: a randomized study.
    Kim SY; Lee SW; Jung SW; Koo JS; Yim HJ; Park JJ; Chun HJ; Lee HS; Choi JH; Kim CD; Ryu HS
    Helicobacter; 2008 Aug; 13(4):282-7. PubMed ID: 18665938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nitazoxanide-based therapeutic regimen as a novel treatment for Helicobacter pylori infection in children and adolescents: a randomized trial.
    Shawky D; Salamah AM; Abd-Elsalam SM; Habba E; Elnaggar MH; Elsawy AA; Baiomy N; Bahaa MM; Gamal RM
    Eur Rev Med Pharmacol Sci; 2022 May; 26(9):3132-3137. PubMed ID: 35587063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of quadruple regimen of clarithromycin added to metronidazole-containing triple therapy against Helicobacter pylori infection following clarithromycin-containing triple-therapy failure.
    Ueki N; Miyake K; Kusunoki M; Shindo T; Kawagoe T; Futagami S; Tsukui T; Inagaki H; Sakamoto C
    Helicobacter; 2009 Apr; 14(2):91-9. PubMed ID: 19298336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seven-day quintuple regimen as a rescue therapy for Helicobacter pylori eradication.
    Mansour-Ghanaei F; Joukar F; Naghipour MR; Forouhari A; Saadat SM
    World J Gastroenterol; 2015 Jan; 21(2):661-6. PubMed ID: 25593496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication.
    Sun Q; Liang X; Zheng Q; Liu W; Xiao S; Gu W; Lu H
    Helicobacter; 2010 Jun; 15(3):233-8. PubMed ID: 20557366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ten-day sequential therapy is more effective than proton pump inhibitor-based therapy in Korea: a prospective, randomized study.
    Oh HS; Lee DH; Seo JY; Cho YR; Kim N; Jeoung SH; Kim JW; Hwang JH; Park YS; Lee SH; Shin CM; Cho HJ; Jung HC; Song IS
    J Gastroenterol Hepatol; 2012 Mar; 27(3):504-9. PubMed ID: 21916989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line eradication rates comparing two shortened non-bismuth quadruple regimens against Helicobacter pylori: an open-label, randomized, multicentre clinical trial.
    Cuadrado-Lavín A; Salcines-Caviedes JR; Diaz-Perez A; Carrascosa MF; Ochagavía M; Fernandez-Forcelledo JL; Cobo M; Fernández-Gil P; Ayestarán B; Sánchez B; Campo C; Llorca J; Lorenzo S; Illaro A
    J Antimicrob Chemother; 2015 Aug; 70(8):2376-81. PubMed ID: 25855760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of two levofloxacin-containing second-line therapies for Helicobacter pylori: a pilot study.
    Calhan T; Kahraman R; Sahin A; Senates E; Doganay HL; Kanat E; Ozdil K; Sokmen HM
    Helicobacter; 2013 Oct; 18(5):378-83. PubMed ID: 23601026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hybrid vs sequential therapy for eradication of Helicobacter pylori in Taiwan: A prospective randomized trial.
    Chen KY; Lin TJ; Lin CL; Lee HC; Wang CK; Wu DC
    World J Gastroenterol; 2015 Sep; 21(36):10435-42. PubMed ID: 26420970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains.
    Molina-Infante J; Pazos-Pacheco C; Vinagre-Rodriguez G; Perez-Gallardo B; Dueñas-Sadornil C; Hernandez-Alonso M; Gonzalez-Garcia G; Mateos-Rodriguez JM; Fernandez-Bermejo M; Gisbert JP
    Helicobacter; 2012 Aug; 17(4):269-76. PubMed ID: 22759326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2-week triple therapy for Helicobacter pylori infection is better than 1-week in clinical practice: a large prospective single-center randomized study.
    Paoluzi P; Iacopini F; Crispino P; Nardi F; Bella A; Rivera M; Rossi P; Gurnari M; Caracciolo F; Zippi M; Pica R
    Helicobacter; 2006 Dec; 11(6):562-8. PubMed ID: 17083378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Standard triple therapy versus sequential therapy for eradication of Helicobacter pylori in treatment naïve and retreat patients.
    Abuhammour A; Dajani A; Nounou M; Zakaria M
    Arab J Gastroenterol; 2016 Sep; 17(3):131-136. PubMed ID: 27665525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized-controlled study to compare the efficacy of sequential therapy with standard triple therapy for Helicobacter pylori eradication in an Irish population.
    Haider RB; Brennan DE; Omorogbe J; Holleran G; Hall B; O'Morain C; Breslin N; O'Connor HJ; Smith SM; McNamara D
    Eur J Gastroenterol Hepatol; 2015 Nov; 27(11):1265-9. PubMed ID: 26287955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of moxifloxacin-based sequential and hybrid therapy for first-line Helicobacter pylori eradication.
    Hwang JJ; Lee DH; Yoon H; Shin CM; Park YS; Kim N
    World J Gastroenterol; 2015 Sep; 21(35):10234-41. PubMed ID: 26401089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen.
    Rokkas T; Sechopoulos P; Robotis I; Margantinis G; Pistiolas D
    Am J Gastroenterol; 2009 Jan; 104(1):21-5. PubMed ID: 19098844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved efficacy of proton pump inhibitor - amoxicillin - clarithromycin triple therapy for Helicobacter pylori eradication in low clarithromycin resistance areas or for tailored therapy.
    Prasertpetmanee S; Mahachai V; Vilaichone RK
    Helicobacter; 2013 Aug; 18(4):270-3. PubMed ID: 23356886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical evaluation of a ten-day regimen with esomeprazole, metronidazole, amoxicillin, and clarithromycin for the eradication of Helicobacter pylori in a high clarithromycin resistance area.
    Georgopoulos SD; Xirouchakis E; Martinez-Gonzalez B; Sgouras DN; Spiliadi C; Mentis AF; Laoudi F
    Helicobacter; 2013 Dec; 18(6):459-67. PubMed ID: 23714140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.